Large-scale testing (Phase 3)Looking for participantsNCT07037433
What this trial is testing
Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity
Who this might be right for
Atherosclerotic Cardiovascular DiseaseOverweightObesity
Amgen 12,800